TransMedics Group, Inc. (TMDX): Price and Financial Metrics


TransMedics Group, Inc. (TMDX)

Today's Latest Price: $12.39 USD

0.26 (-2.06%)

Updated Oct 29 4:00pm

Add TMDX to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 142 in Medical - Devices & Equipment

See all "A" rated Strong Buy stocks

TMDX Stock Summary

  • TMDX's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 0.21 -- higher than just 4.51% of US-listed equities with positive expected earnings growth.
  • TMDX's went public 1.5 years ago, making it older than merely 1.94% of listed US stocks we're tracking.
  • With a price/sales ratio of 14.2, TransMedics Group Inc has a higher such ratio than 89.77% of stocks in our set.
  • If you're looking for stocks that are quantitatively similar to TransMedics Group Inc, a group of peers worth examining would be NWBO, MOSY, ASTC, KMDA, and UTSI.
  • TMDX's SEC filings can be seen here. And to visit TransMedics Group Inc's official web site, go to www.transmedics.com.

TMDX Stock Price Chart Interactive Chart >

Price chart for TMDX

TMDX Price/Volume Stats

Current price $12.39 52-week high $20.99
Prev. close $12.65 52-week low $10.10
Day low $12.37 Volume 79,300
Day high $12.80 Avg. volume 169,620
50-day MA $15.12 Dividend yield N/A
200-day MA $16.08 Market Cap 336.45M

TransMedics Group, Inc. (TMDX) Company Bio


TransMedics Group, Inc. is a commercial stage medical technology company, which engages in the development and commercialization of organ care system platform. It focuses on the preservation of human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation. The company was founded by Waleed H. Hassanein in October 2018 and is headquartered in Andover, MA.


TMDX Latest News Stream


Event/Time News Detail
Loading, please wait...

TMDX Latest Social Stream


Loading social stream, please wait...

View Full TMDX Social Stream

Latest TMDX News From Around the Web

Below are the latest news stories about TransMedics Group Inc that investors may wish to consider to help them evaluate TMDX as an investment opportunity.

FDA postpones Ad Com meeting on TransMedics donor heart management system

TransMedics (TMDX) has announced that the FDA has temporarily postponed the Advisory Committee (AdCom) meeting to review its premarket approval application for its OCS Heart, which was originally scheduled for October 7, to have more time to review additional and longer-term data from the OCS Heart EXPAND trial and EXPAND Continued...

Seeking Alpha | September 28, 2020

TransMedics (TMDX) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

TransMedics (TMDX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | July 29, 2020

TransMedics to Report Second Quarter 2020 Financial Results on August 5, 2020

ANDOVER, Mass., July 23, 2020 (GLOBE NEWSWIRE) -- TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the second quarter after market close on Wednesday, August 5, 2020. The TransMedics management team will host a corresponding conference call beginning at 4:30 p.m. ET / 1:30 p.m. PT. Investors interested in listening to the conference call may do so by dialing (866) 221-1172 for domestic callers or (270) 215-9603 for international callers, followed by Conference ID: 9858896. A live and archived webcast of the event will be available on the “Investors” section of the TransMedics website at ht...

Yahoo | July 23, 2020

TransMedics: A Medical Device Company Creating A Healthy Ecosystem

Transplant patients have advanced disease states that are best addressed by replacing the ailing organ with a healthy one from a donor. Otherwise, administering care to such critically ill patients carries extremely high cost despite having limited benefits to longevity or quality of life. Unfortunately, almost five patients die each...

Christopher Hillary | June 5, 2020

Why TransMedics Group Is Plunging Today

Shares of TransMedics Group (NASDAQ: TMDX), a medical device company focused on organ transportation, fell about 16% as of 10:37 a.m. EDT on Wednesday after the company announced the pricing details of a common stock offering. TransMedics let investors know on Tuesday that it wanted to raise about $60 million through a secondary common-stock offering. TransMedics is selling 5 million shares for $14 each.

Yahoo | May 27, 2020

Read More 'TMDX' Stories Here

TMDX Price Returns

1-mo -10.09%
3-mo -31.40%
6-mo -25.32%
1-year -30.94%
3-year N/A
5-year N/A
YTD -34.82%
2019 N/A
2018 N/A
2017 N/A
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.7235 seconds.